We can’t show the full text here under this license. Use the link below to read it at the source.
The effect of beinaglutide as an glucagon-like peptide-1 receptor agonists on cardiometabolic factors: a systematic review and meta-analysis
Beinaglutide’s effects on heart and metabolism health factors: a review and combined analysis
AI simplified
Abstract
Beinaglutide significantly reduced weight by 3.74 kg in a meta-analysis of 872 participants across 7 studies.
- Beinaglutide is associated with a significant decrease in body mass index (BMI) by 1.64 kg/m.
- Waist circumference (WC) decreased by 3.19 cm with Beinaglutide treatment.
- Triglyceride (TG) levels were lowered by 0.14 mmol/l due to Beinaglutide.
- Systolic blood pressure (SBP) showed a reduction of 1.76 mm/Hg with this treatment.
- Greater reductions in weight and triglycerides were observed with interventions lasting more than 12 weeks.
- Lower doses of Beinaglutide (less than 0.4 mg) resulted in greater weight loss compared to higher doses.
AI simplified
Key numbers
-3.74 kg
Weight Reduction
in weight from baseline
-1.76 mm/Hg
Decrease
in
-0.14 mmol/l
Triglyceride Level Reduction
in triglyceride levels